Formulary Watch |

A breast cancer drug is the first approval from FDA in 2 new pilot programs that make the development and review of cancer drugs more efficient.

FDA’s approval of an expanded indication for a prostate cancer drug could net 2 pharmaceutical manufacturers billions of dollars.

Pharma makers are voluntarily recalling several drugs containing this active ingredient, used to treat high blood pressure and heart failure, since they may contain a carcinogen.

FDA okayed the first treatment for chronic sialorrhea, or excessive drooling, in adult patients.

A pharma maker is under fire for raising prices on its cancer drugs. Meanwhile, there were two major cancer drug approvals in June. Here are the top 3 cancer news articles in the past month.

FDA approved a novel device to treat breathing difficulty associated with severe emphysema.

A combination melanoma treatment that was just approved by FDA is available through select specialty pharmacies.

FDA’s approval of a cannabidiol (CBD) medicine to treat seizures associated with 2 severe forms of epilepsy is a positive sign for other CBD drugs under development.

The manufacturer of bevacizumab (Avastin), snagged FDA approval for yet another type of cancer.

FDA approved the first biosimilar to Neulasta, as well as a new combination treatment for osteoarthritis pain and hypertension and a new drug to treat chronic lymphocytic leukemia.

The manufacturer of two cancer drugs hiked the price on the medicines despite President Donald Trump’s new plan to lower drug prices.

FDA is warning that 2 liquid-filled intragastric balloon systems used to treat obesity are causing deaths in some patients

FDA’s new guidances on Risk Evaluation and Mitigation Strategy (REMS) requirements aims to help generic and biosimilar drugs get to market faster.

FDA is asking manufacturers to immediately stop selling OTC products containing the pain reliever benzocaine (such as Orajel) for teething in infants or children.

While the pharmaceutical industry has made tremendous advances in new drug development this year, FDA has also had to remove drugs from the market or investigate problem drugs. Here are the top 3 drug warnings and problems so far in 2018.

The first smallpox treatment, being developed for the United States government in the case of a bioterrorism attack, could be available as early as August.

A combination cancer treatment has been expanded to include treating both melanoma and anaplastic thyroid cancer (ATC).

A new draft guidance document from FDA aims to help pharmaceutical manufacturers develop new medications to treat opioid use disorder.

FDA approved a new treatment for non-small cell lung cancer, as well as drugs to treat chronic immune thrombocytopenia and a rare form of childhood rickets.

FDA is permitting marketing of the first medical device that uses artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy.

FDA approved a new indication for Exparel Bupivacaine Liposome injectable suspension (Exparel, Pacira) for use as a nerve block to produce post-surgical regional analgesia following shoulder surgery in adults.